BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
AGREEMENTS: Name Products Content of Agreement Date
Biosource
oncology, infectious joint R&D
1/96
Technologies disease, and
inflammation treatments
agreement
Dura
SRI's jet milling process licensing agreement 7/97
Pharmaceuticals for protein and peptide
formulations of dry
powder drugs for use
with Dura's Spiros
pulmonary drug delivery
technology
MDS Panlabs, combinatorial chemistry technology access 3/98
Tripos Inc., libraries for designing agreement--Tripos
Genelabs
small molecule
will design
Technologies Inc. compounds that bind compounds via
double-stranded DNA molecular modeling,
MDS Panlabs will
synthesize
compounds, SRI
(working
independently) will
use solid-phase
combinatorial
synthesis to make
molecules to
Genelabs
specifications
Taiho
endocrine approach for research agreement 10/96
Pharmaceutical chemotherapy in
Co. Ltd.
estrogen-dependent
breast cancer
RESEARCH & DEVELOPMENT: Pharmaceutical Discovery and Screening: custom drug design, synthesis
and efficacy screens for drug development of: antibacterials; antivirals;
anticancer agents; lipid-lowering agents; neurobiological therapeutics;
women's health therapeutics; steroids (anti-inflammation, hormone analogs,
vitamin analogs, neuroprotection); and other synthetic drugs (anticancer,
anti-inflammation, anti-angiogenesis, nootropics, cardiovascular, CNS,
neuroprotection), combinatorial chemistry; radiolabeled synthesis; process
development; scale-up
Biopharmaceutical Development: pharmacology, mammalian toxicology;
molecular and genetic toxicology; microbiology, pharmacokinetic and
metabolism studies; in vitro comparative metabolism; immunology and
immunotoxicology; cGMP manufacturing; formulation design;
preformulation; stability monitoring; analytical chemistry
Drug Delivery: transdermal; topical; controlled release; standard
formulations (oral, injectable, topical); alternative drug delivery (aerosols,
nasal, controlled release, microencapsulation, taste masking, bioerodable
polymers, protein peptide delivery)
PRODUCTS IN DEVELOPMENT: Name Status
Edatrexate (with Memorial Sloan Kettering) in Phase I clinicals
Tirapazamine (with Sanofi) in Phase III clinicals
SR 4980 in preclinicals
SR 14005 in preclinicals
SR 14110 in preclinicals
SR 14115 in preclinicals
SR 4554 (with CRCT) in preclinicals
SR 16234 (TAS-108) (with Taiho) in preclinicals
*pipeline as of 10/05
Copyright ©2006 AHC Media ® 355